Ionis Pharmaceuticals, Inc. Revenue
Ionis Pharmaceuticals, Inc. (IONS) reported Revenue of $203.33 million for the 3-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. revenues for the quarter ending 2025-12-31 was $203.33M, a 10.26% decline year-over-year.
- Ionis Pharmaceuticals, Inc. revenues for the quarter ending 2024-12-31 was $226.58M, a 30.18% decline year-over-year.
- Ionis Pharmaceuticals, Inc. revenues for the quarter ending 2023-12-31 was $324.50M, a 113.64% increase year-over-year.
- Ionis Pharmaceuticals, Inc. revenues for the quarter ending 2022-12-31 was $151.89M, a 65.48% decline year-over-year.
- Ionis Pharmaceuticals, Inc. revenues for fiscal 2017 was $507.67M, a 46.46% increase from fiscal 2016.
- Ionis Pharmaceuticals, Inc. revenues for fiscal 2016 was $346.62M, a 22.18% increase from fiscal 2015.
- Ionis Pharmaceuticals, Inc. revenues for fiscal 2015 was $283.70M, a 32.47% increase from fiscal 2014.
- Ionis Pharmaceuticals, Inc. revenues for fiscal 2014 was $214.16M, a 45.41% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $203.33M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $226.58M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $324.50M 10-K · filed 2025-02-19 | ||||
| 2022-12-31 | $151.89M 10-K · filed 2024-02-21 | ||||
| 2021-12-31 | $440.01M 10-K · filed 2023-02-22 | ||||
| 2020-12-31 | $290.28M 10-K · filed 2022-02-25 | ||||
| 2019-12-31 | $493.68M 10-K · filed 2021-02-24 | $661.57M derived: sum of 2 quarters · filed 2021-02-24 | $825.38M derived: sum of 3 quarters · filed 2021-02-24 | $1.12B derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-09-30 | $167.89M 10-K · filed 2020-03-02 | $331.70M derived: sum of 2 quarters · filed 2020-03-02 | $628.92M derived: sum of 3 quarters · filed 2020-03-02 | $821.03M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2019-06-30 | $163.81M 10-K · filed 2020-03-02 | $461.03M derived: sum of 2 quarters · filed 2020-03-02 | $653.14M derived: sum of 3 quarters · filed 2020-03-02 | $798.53M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2019-03-31 | $297.21M 10-K · filed 2020-03-02 | $489.33M derived: sum of 2 quarters · filed 2020-03-02 | $634.72M derived: sum of 3 quarters · filed 2020-03-02 | $752.47M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-12-31 | $192.11M 10-K · filed 2020-03-02 | $337.51M derived: sum of 2 quarters · filed 2020-03-02 | $455.25M derived: sum of 3 quarters · filed 2020-03-02 | $599.67M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-09-30 | $145.40M 10-K · filed 2020-03-02 | $263.14M derived: sum of 2 quarters · filed 2020-03-02 | $407.56M derived: sum of 3 quarters · filed 2020-03-02 | $575.35M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $117.75M 10-K · filed 2020-03-02 | $262.17M derived: sum of 2 quarters · filed 2020-03-02 | $429.96M derived: sum of 3 quarters · filed 2020-03-02 | $548.27M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $144.42M 10-K · filed 2020-03-02 | $312.21M derived: sum of 2 quarters · filed 2020-03-02 | $430.52M derived: sum of 3 quarters · filed 2020-03-02 | $542.80M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $167.79M 10-K · filed 2019-03-01 | $172.30M 10-K · filed 2018-02-28 | $286.11M derived: sum of 2 quarters · filed 2019-03-01 | $398.38M derived: sum of 3 quarters · filed 2019-03-01 | $507.67M 10-K · filed 2018-02-28 |
| 2017-09-30 | $118.31M 10-K · filed 2019-03-01 | $120.91M 10-Q · filed 2017-11-07 | $230.59M derived: sum of 2 quarters · filed 2019-03-01 | $335.37M 10-Q · filed 2017-11-07 | $506.74M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $112.27M 10-K · filed 2019-03-01 | $104.15M 10-Q · filed 2017-08-09 | $214.46M 10-Q · filed 2017-08-09 | $388.42M derived: sum of 3 quarters · filed 2019-03-01 | $499.35M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $115.80M 10-K · filed 2019-03-01 | $110.30M 10-Q · filed 2017-05-09 | $276.15M derived: sum of 2 quarters · filed 2019-03-01 | $387.08M derived: sum of 3 quarters · filed 2019-03-01 | $425.55M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $160.35M 10-K · filed 2018-02-28 | $271.28M derived: sum of 2 quarters · filed 2018-02-28 | $309.75M derived: sum of 3 quarters · filed 2018-02-28 | $346.62M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $110.93M 10-K · filed 2018-02-28 | $149.40M derived: sum of 2 quarters · filed 2018-02-28 | $186.27M 10-Q · filed 2017-11-07 | $237.84M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $38.47M 10-K · filed 2018-02-28 | $75.34M 10-Q · filed 2017-08-09 | $126.92M derived: sum of 3 quarters · filed 2018-02-28 | $176.04M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $36.87M 10-K · filed 2018-02-28 | $88.44M derived: sum of 2 quarters · filed 2018-02-28 | $137.57M derived: sum of 3 quarters · filed 2018-02-28 | $257.99M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2015-12-31 | $51.57M 10-K · filed 2017-03-01 | $100.69M derived: sum of 2 quarters · filed 2017-03-01 | $221.12M derived: sum of 3 quarters · filed 2017-03-01 | $283.70M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $49.12M 10-K · filed 2017-03-01 | $169.55M derived: sum of 2 quarters · filed 2017-03-01 | $232.13M 10-Q · filed 2016-11-09 | $316.99M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $120.43M 10-K · filed 2017-03-01 | $183.01M 10-Q · filed 2016-08-09 | $267.87M derived: sum of 3 quarters · filed 2017-03-01 | $311.94M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $62.58M 10-K · filed 2017-03-01 | $147.44M derived: sum of 2 quarters · filed 2017-03-01 | $191.51M derived: sum of 3 quarters · filed 2017-03-01 | $248.58M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $84.86M 10-K · filed 2016-02-26 | $128.92M derived: sum of 2 quarters · filed 2016-02-26 | $186.00M derived: sum of 3 quarters · filed 2016-02-26 | $214.16M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $44.06M 10-K · filed 2016-02-26 | $101.14M derived: sum of 2 quarters · filed 2016-02-26 | $129.30M 10-Q · filed 2015-11-09 | $171.55M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $57.08M 10-K · filed 2016-02-26 | $85.24M 10-Q · filed 2015-08-05 | $127.48M derived: sum of 3 quarters · filed 2016-02-26 | $151.07M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $28.16M 10-K · filed 2016-02-26 | $70.41M derived: sum of 2 quarters · filed 2016-02-26 | $93.99M derived: sum of 3 quarters · filed 2016-02-26 | $132.09M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2013-12-31 | $42.25M 10-K · filed 2015-03-02 | $65.83M derived: sum of 2 quarters · filed 2015-03-02 | $103.92M derived: sum of 3 quarters · filed 2015-03-02 | $147.28M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $23.59M 10-K · filed 2015-03-02 | $61.68M derived: sum of 2 quarters · filed 2015-03-02 | $105.04M 10-Q · filed 2014-11-07 | $124.91M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | $38.09M 10-K · filed 2015-03-02 | $81.45M 10-Q · filed 2014-08-04 | $101.33M derived: sum of 3 quarters · filed 2015-03-02 | $112.93M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | $43.36M 10-K · filed 2015-03-02 | $63.23M derived: sum of 2 quarters · filed 2015-03-02 | $74.83M derived: sum of 3 quarters · filed 2015-03-02 | $122.17M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | $19.87M 10-K · filed 2014-03-03 | $31.47M derived: sum of 2 quarters · filed 2014-03-03 | $78.81M derived: sum of 3 quarters · filed 2014-03-03 | $102.05M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $11.60M 10-K · filed 2014-03-03 | $58.94M derived: sum of 2 quarters · filed 2014-03-03 | $82.18M 10-Q · filed 2013-11-05 | $114.58M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-06-30 | $47.34M 10-K · filed 2014-03-03 | $70.58M 10-Q · filed 2013-08-06 | $102.98M derived: sum of 3 quarters · filed 2014-03-03 | $123.69M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-03-31 | $23.23M 10-K · filed 2014-03-03 | $55.64M derived: sum of 2 quarters · filed 2014-03-03 | $76.35M derived: sum of 3 quarters · filed 2014-03-03 | $101.17M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2011-12-31 | $32.40M 10-K · filed 2013-02-28 | $53.12M derived: sum of 2 quarters · filed 2013-02-28 | $77.94M derived: sum of 3 quarters · filed 2013-02-28 | $99.09M 10-K · filed 2014-03-03 | |
| 2011-09-30 | $20.71M 10-K · filed 2013-02-28 | $45.54M derived: sum of 2 quarters · filed 2013-02-28 | $66.68M 10-Q · filed 2012-11-06 | $93.10M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-06-30 | $24.82M 10-K · filed 2013-02-28 | $45.97M 10-Q · filed 2012-08-06 | $72.39M derived: sum of 3 quarters · filed 2013-02-28 | $101.01M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-03-31 | $21.15M 10-K · filed 2013-02-28 | $47.57M derived: sum of 2 quarters · filed 2013-02-28 | $76.19M derived: sum of 3 quarters · filed 2013-02-28 | $99.69M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2010-12-31 | $26.42M 10-K · filed 2012-02-29 | $55.04M derived: sum of 2 quarters · filed 2012-02-29 | $78.55M derived: sum of 3 quarters · filed 2012-02-29 | $108.47M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $28.62M 10-K · filed 2012-02-29 | $52.13M derived: sum of 2 quarters · filed 2012-02-29 | $82.05M 10-Q · filed 2011-11-08 | $114.31M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-06-30 | $23.50M 10-K · filed 2012-02-29 | $53.43M 10-Q · filed 2011-08-08 | $85.69M derived: sum of 3 quarters · filed 2012-02-29 | $112.46M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-03-31 | $29.93M 10-K · filed 2012-02-29 | $62.19M derived: sum of 2 quarters · filed 2012-02-29 | $88.96M derived: sum of 3 quarters · filed 2012-02-29 | $119.95M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2009-12-31 | $32.26M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $59.03M derived: sum of 2 quarters · filed 2012-02-29 | $90.02M derived: sum of 3 quarters · filed 2012-02-29 | $121.60M 10-K · filed 2012-02-29 | |
| 2009-09-30 | $26.77M 10-Q · filed 2010-11-05 | $57.76M derived: sum of 2 quarters · filed 2010-11-05 | $89.34M 10-Q · filed 2010-11-05 | ||
| 2009-06-30 | $30.99M 10-Q · filed 2010-08-09 | $62.57M 10-Q · filed 2010-08-09 | |||
| 2008-12-31 | $107.19M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |